Capital Advisory Group Advisory Services’s CRISPR Therapeutics CRSP Stock Holding History

Capital Advisory Group Advisory Services’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-62	Closed	-$4K	–	266
2022 Q1	$4K	Buy	+62	New	+$3.89K	﹤0.01%	446
2021 Q4	–	Sell	-62	Closed	-$7K	–	236
2021 Q3	$7K	Sell	62 -186	-75%	-$23.4K	﹤0.01%	431
2021 Q2	$40K	Hold	248	–	–	0.01%	281
2021 Q1	$30K	Hold	248	–	–	0.01%	277
2020 Q4	$38K	Buy	248 +186	+300%	+$22K	0.02%	262
2020 Q3	$5K	Buy	+62	New	+$5.5K	﹤0.01%	377

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Capital Advisory Group Advisory Services's CRSP Position: Q2 2022 in Review

Capital Advisory Group Advisory Services sold out of CRISPR Therapeutics (CRSP) in Q2 2022, closing a stake of 62 shares — an estimated $4K sold.

Capital Advisory Group Advisory Services first reported a position in CRSP in Q3 2020 and held it in 6 quarters. The position peaked at $40K in Q2 2021. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

Capital Advisory Group Advisory Services reported no remaining CRISPR Therapeutics position as of Q2 2022 after selling out during the quarter.
Capital Advisory Group Advisory Services sold 62 CRISPR Therapeutics shares in Q2 2022, an estimated $4K.
Capital Advisory Group Advisory Services first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 6 quarters.
Capital Advisory Group Advisory Services's CRISPR Therapeutics position peaked at $40K in Q2 2021.
435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on Capital Advisory Group Advisory Services's 13F filing for Q2 2022, filed 12 Aug 2022.